Inspiremd Stock Price, News & Analysis

InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system, announced that its Compensation Committee has approved inducement grants for a new non-executive employee. The grant consists of 18,000 shares of restricted stock, issued outside the company's 2021 Equity Compensation Plan, with a grant date of January 7, 2025.

The restricted stock will vest over three years, with one-third vesting on the first anniversary and the remaining portions vesting equally on the second and third anniversaries, contingent upon continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is specifically designed for new employees or those returning after a bona fide period of non-employment.

InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system, has announced inducement grants for nine new non-executive employees. The Compensation Committee approved a total of 372,135 shares of restricted stock outside the company's 2021 Equity Compensation Plan, with a grant date of January 7, 2025.

The restricted stock grants are structured with a three-year vesting period: one-third vests after the first year, with the remaining shares vesting equally on the second and third anniversaries of the grant date. These grants, made under Nasdaq Listing Rule 5635(c)(4), are specifically designed as employment inducements for new hires who were not previously InspireMD employees.

InspireMD (NSPR) announced that Chief Financial Officer Craig Shore will retire after 15 years with the company. Shore will remain in his position until a successor is appointed and will assist in the transition. The announcement comes as the company anticipates potential FDA approval in the first half of 2025 for its CGuard™ Embolic Prevention Stent System.

CEO Marvin Slosman praised Shore's commitment to building the company's position as a global leader in carotid interventions. Shore expressed confidence in the company's future growth trajectory and its leadership in carotid intervention and stroke prevention. The company has initiated a search for a new CFO.

InspireMD (NSPR) has announced the enrollment of its first patient in the CGUARDIANS II clinical trial, evaluating the CGuard Prime Carotid Stent System in TCAR procedures. The study, conducted at Good Samaritan Hospital in Cincinnati, enrolled its first patient under Dr. Patrick Muck, who serves as both site principal investigator and co-lead investigator.

The CGUARDIANS II is a prospective, multi-center, single-arm pivotal study aiming to enroll a minimum of 50 evaluable patients. The trial will evaluate acute device success and technical success of CGuard Prime when used with FDA-cleared TCAR neuro-protection systems. The company is approaching potential FDA approval for CGuard Prime with a CAS indication in first half of next year, targeting a TCAR market of approximately 30,000 U.S. procedures annually.

InspireMD (NSPR) has appointed Scott R. Ward to its Board of Directors. Ward, who most recently served as CEO and President of Cardiovascular Systems until its acquisition by Abbott in April 2023, brings over 40 years of healthcare industry experience, including 30 years at Medtronic in senior leadership roles. The appointment comes as InspireMD approaches potential U.S. approval of its CGuard Prime carotid stent system. Ward's extensive operational experience in the cardiovascular space is expected to contribute to the company's strategy in advancing its carotid platform and pipeline innovations, including CAS, TCAR, and Neuro focus.

InspireMD (NSPR) reported Q3 2024 financial results, highlighting record quarterly revenue of $1.81 million, a 16.3% increase year-over-year, with 3,129 CGuard stents sold. The company submitted a Premarket Approval application to FDA for CGuard Prime carotid stent system and received IDE approval for CGUARDIANS II pivotal study. Net loss widened to $7.89 million ($0.16 per share) from $5.18 million in Q3 2023. Cash position stood at $40.4 million as of September 30, 2024. The company established new headquarters in Miami, Florida, anticipating U.S. commercial launch in H1 2025, pending approval.

InspireMD (Nasdaq: NSPR) has granted inducement awards to five new non-executive employees totaling 197,167 shares of restricted stock. The grants, made outside the company's 2021 Equity Compensation Plan, were approved by the Compensation Committee on October 24, 2024. The restricted stock will vest over three years: one-third after the first year and the remaining two-thirds in equal installments on the second and third anniversaries, contingent on continued employment.

InspireMD (NSPR), developer of the CGuard™ Embolic Prevention Stent System for Carotid Artery Disease and stroke prevention, has scheduled its Third Quarter 2024 financial results announcement for Tuesday, November 12th, 2024, before market open. The company will host a conference call and webcast at 8:30 AM EDT to discuss financial results and provide corporate updates. The call will be accessible via toll-free (1-800-225-9448) and international (1-203-518-9708) numbers, with conference ID: IMD3Q24. A webcast will be available through the company's website.

InspireMD (Nasdaq: NSPR) has announced the establishment of its global headquarters in Miami, Florida. This strategic move is aimed at supporting the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system in the first half of 2025, pending FDA approval.

The new facility will play a important role in driving long-term growth and serving the U.S. market. InspireMD is currently building world-class commercial and operational teams, along with supporting infrastructure. The company's leadership team views South Florida as an ideal location due to its rich history of medical device innovation and access to talent.

InspireMD is actively building its marketing, training, and sales operations teams in South Florida to form the foundation of its U.S. commercial organization. The company recently submitted the final module of its Premarket Authorization (PMA) application to the FDA for the CGuard Prime carotid stent system on September 16th.